<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681823</url>
  </required_header>
  <id_info>
    <org_study_id>MMC12192-12CTIL</org_study_id>
    <nct_id>NCT01681823</nct_id>
  </id_info>
  <brief_title>Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA</brief_title>
  <official_title>Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EcoNugenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EcoNugenics</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the oral administration of PectaSol-C Modified Citrus Pectin (MCP) is
      effective at improving Prostate Specific Antigen (PSA) kinetics in men with biochemical
      relapsed prostate cancer and serial increases in PSA levels. Also, documentation of any side
      effects or benefits within parameter of the study is included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study on the effect of PectaSol-C Modified Citrus Pectin (MCP) with subjects selected
      on the basis of documented PC post local therapy, and biochemical relapse, with linear
      progression of at least 3 PSA tests in at least 3 months. After initial screening, treatment
      {4.8 grams (6 capsules) three times a day away from meals} will continue for 6 months
      provided patients are showing benefit and tolerating the therapy well. Patient tolerability
      of MCP will be assessed by comparing the results of monthly self-assessment diaries with
      baseline assessments.

      Prostate cancer is the most common cancer among men, except for non melanoma skin cancer. It
      is the second leading cause of cancer related death in men. About 33% of prostate cancer
      patients treated with primary therapy (surgery or radiation) will recur in the form of non
      metastatic biochemically relapsed prostate cancer (BRPC-M0). In these patients, PSA is
      rising while scans are negative for metastasis. Recent surveys demonstrated that
      approximately 40% of prostate cancer patients use various complementary and alternative
      medicine modalities as a component of therapy. Currently, there is no standard treatment for
      biochemical failure with proven benefits. Patients are being encouraged to enroll in
      clinical trials to help establish standards of care. Studies have shown that in 80% of
      patients with BRPC-M0, PSA will rise by at least 25% every 6 months.

      Native pectin is a complex carbohydrate soluble fiber. Dietary fibers, such as pectin, have
      been shown to have positive effects on a wide spectrum of pathological conditions. Their
      positive influence on human health is explained by their antioxidative, hypocholesterolemic,
      and anticancer effects. MCP is composed of short, slightly-branched, carbohydrate chains
      derived from the soluble albedo fraction of citrus fruit peels, which have been altered by
      decreasing the molecular weight and degree of esterification using pH, temperature, and a
      controlled enzymatic process. This specific modification is critical as it allows for the
      absorption of MCP into the circulatory system and ensures its targeted bioactivity
      throughout the body. MCP is relatively rich in galactose and thus antagonizes the binding
      protein galectin-3 which results in suppression of cancer cell aggregation, adhesion, and
      metastasis. MCP acts as a ligand for galectin-3, which plays a major role in tumor formation
      and progression. It has been shown using a combination of fluorescence microscopy, flow
      cytometry, and atomic force microscopy, that pectin galactan specifically binds to the
      recombinant form of human galectin-3.

      MCP showed anti-metastatic effects on cancer cells in multiple in vitro and in vivo studies.
      MCP inhibits carbohydrate mediated tumor growth, angiogenesis and metastasis via effects on
      galectin-3 function as demonstrated in an animal study on MCP's inhibition of breast and
      colon cancer progression. Results demonstrated a 70.2% reduction in breast tumor growth, a
      66% reduction in breast angiogenesis, and 0% breast to lung metastasis compared to 100% in
      the control group; 0% colon to liver metastasis compared to 60% in the control group; and
      25% colon to lymph metastasis compared to 100% in the control group. In an earlier study
      oral intake of MCP had been shown to act as a potent inhibitor of spontaneous prostate
      carcinoma metastasis in an animal model, demonstrating a significant 56% reduction in lung
      metastases. Human cancer cell lines (LNCaP androgen dependent &amp; PC3 androgen independent)
      and mouse prostate cancer cell lines (CASP2-1 androgen dependent and CASP1-1 androgen
      independent) treated with 1% MCP showed the following cytotoxicity due to induced apoptosis:
      52.28% in LNCaP; 48.16% in PC3; 23.03% in CASP2-1; and 49.01% in CASP1-1.13 The effects of
      MCP on cell-cell and cell-matrix interactions mediated by carbohydrate-recognition were
      investigated by looking at MCP-inhibited B16-F1 melanoma cells adhesion and aggregation. MCP
      was shown to inhibit anchorage-independent growth of B16-F1 cells. These results indicate
      that carbohydrate-recognition by cell surface galectin-3 is involved in cell-extracellular
      matrix interaction and plays a role in anchorage-independent growth as well as the in vivo
      embolization of tumor cells. The modulation of the lung colonization of B16-F1 melanoma
      cells by MCP was first observed in 1992 when injection of MCP significantly decreased B16-F1
      experimental metastasis (greater than 90%). Galectin-3 participation in the adhesion of the
      MDA-MB-435 cells to the endothelium was observed by the clustering of galectin-3 on
      endothelial cells at the sites of the contact with tumor cells, suggesting its potential
      functional significance for anti-adhesive therapy of cancer metastasis. The anti-metastatic
      effect of MCP has also been shown in reduced liver metastasis in a dose-dependent manner.
      The use of MCP in combination with the chemotherapy drug doxorubicin has demonstrated an
      increased cytotoxicity effect of inducing rapid cell death in prostate cancer cell lines
      DU-145 (androgen independent) through apoptosis, and in LNCaP (androgen dependant) through
      cell cycle arrest (G2-M arrest). These results show promise for the use of MCP with
      doxorubicin as an adjuvant to chemotherapy which may allow for lower dosage of the cancer
      drug to be used with less toxicity. A human clinical pilot trial with MCP showed an increase
      in prostate specific antigen doubling time, a marker of slowing the progression of prostate
      cancer. Clinical research on MCP also demonstrated a significant improvement in quality of
      life and stabilization of disease for patients with advanced solid tumors.

      In addition to its therapeutic roles against cancer, MCP has been shown to remove toxic
      metals from the body without affecting essential minerals. In a clinical study, baseline
      levels of heavy metals and essential minerals were established with 24-hours urine
      collection prior to oral administration of MCP. 24-hours urine collection was repeated on
      days 1 and 6. Urinary excretion of lead, mercury, cadmium, and arsenic increased
      significantly, essential minerals were not changed significantly and no side effects were
      reported. In a hospital study in China, children with lead toxicity were given MCP. Their
      blood serum levels went down while corresponding lead levels in their urine increased
      significantly, without side effects.

      MCP has immunostimulatory properties as demonstrated in human blood samples, including the
      activation of functional NK cells against K562 leukemic cells in culture: Unsaturated
      oligogalacturonic acids appear to be the immunostimulatory carbohydrates in MCP. Human blood
      samples collected from healthy volunteers were incubated with increasing concentrations of
      MCP and antibodies. After 24-hours, blood-antibody mix was lysed and run on a flow cytometer
      using a 3-color protocol and the % of activated T-cytotoxic cell subset, B-cell, and
      NK-cells, and % increase over untreated control calculated and a significant dose dependent
      activation was seen. The ability of the activated NK cells to induce leukemia cell death was
      analyzed by co-incubating MCP-treated lymphocytes with K562 T-cell leukemia cells and
      induced leukemia cell death was determined to be greater than 50%.

      MCP has been demonstrated to be protective in experimental nephropathy  with modulation of
      early proliferation and later galectin-3 expression,  apoptosis and fibrosis by
      experimentally modulating galectin-3 in folic acid  (FA)-induced acute kidney injury.  Mice
      were pre-treated with normal or 1%  MCP-supplemented drinking water one week before FA
      injection. During the  initial injury phase, all FA treated mice lost weight whilst their
      kidneys enlarged secondary to the renal insult; these gross changes were significantly
      lessened in the MCP group but this was not associated with significant changes in galectin-3
      expression. At a histological level, MCP clearly reduced renal cell proliferation but did
      not affect apoptosis. Later, during the recovery  phase at two weeks, MCP-treated mice
      demonstrated reduced galectin-3 in  association with decreased renal fibrosis, macrophages,
      proinflammatory  cytokine expression and apoptosis. Galectin-3 inhibition by MCP was
      demonstrated to block Aldosterone (Aldo) induced collagen type I synthesis. Rats were
      treated with Aldo-salt combined MCP for 3 weeks. Hypertensive Aldo-treated rats presented
      vascular hypertrophy, inflammation, fibrosis, and increased aortic Gal-3 expression. MCP
      treatment reversed all the above effects.

      MCP is affirmed as GRAS (generally regarded as safe) under the US Code of Federal Regulation
      21CFR184.1588.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Prostate Specific Antigen (PSA) kinetics in men with biochemical relapsed prostate cancer and serial increases in PSA levels.</measure>
    <time_frame>6 month endpoint.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSA doubling time increase will be used to show effectiveness of the Modified Citrus pectin (MCP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>An assessment of adverse side effects due to Modified Citrus Pectin (MCP).</measure>
    <time_frame>6 month endpoint.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patient tolerability of MCP will be assessed by comparing the results of weekly self-assessment diaries with baseline assessments.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood Serum Analysis (Galectin-3, C-Reactive Protein, Lipid Panels)</measure>
    <time_frame>6 month endpoint.</time_frame>
    <safety_issue>No</safety_issue>
    <description>At baseline (0 month), and end of study (6 month): Blood draw for serum levels of galectin-3, C-reactive protein, and lipid panel.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>PectaSol-C Modified Citrus Pectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PectaSol-C Modified Citrus Pectin (MCP)</intervention_name>
    <description>Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).</description>
    <arm_group_label>PectaSol-C Modified Citrus Pectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented PC post local therapy with undetectable Prostate Specific Antigen (PSA),
             and biochemical relapse (defined as post-surgery PSA &gt; 0.2 ng/ml; post-radiation &gt;
             nadir +2 ng/ml, the PSA nadir is the lowest PSA reading achieved after treatment),
             with linear progression of at least 3 PSA tests in at least 3 months before the
             commencement of the trial.

          -  All patients must have negative bone scan and CT scan for the chest-abdomen-pelvis
             within 2 weeks prior to study initiation.

        Exclusion Criteria:

          -  Psychological, familial, sociological or geographical conditions that may interfere
             with compliance with the study or prevent completion or compliance of protocol.

          -  Other severe or poorly controlled medical condition(s).

          -  Known allergies to any of the ingredients.

          -  Hormonal therapy or other therapy for PC in the last 3 months.

          -  Positive bone scan or CT scan of the chest-abdomen-pelvis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Keizman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isaac Eliaz, MD, LAc, MS</last_name>
    <role>Study Director</role>
    <affiliation>Amitabha Medical Clinic and Healing Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moshe Frenkel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Associate Professor, University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Keizman, M.D.</last_name>
    <phone>+972 (0)9 747 2714</phone>
    <email>danielkeizman@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moshe Frenkel, M.D.</last_name>
    <phone>+972 (0)52 331 1255</phone>
    <email>office@moshefrenkelmd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Tshernichovsky 59,</name>
      <address>
        <city>Kfar-Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Keizman, M.D.</last_name>
      <phone>+972 (0)9 747 2714</phone>
      <email>danielkeizman@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Berkley</last_name>
      <phone>+972 (0)9 747 2101</phone>
      <email>sharon.berkley@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Keizman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Keizman D, Maimon N, Gottfried M. Metastatic Hormone Refractory Prostate Cancer : Recent Advances in Standard Treatment Paradigm, and Future Directions. Am J Clin Oncol. 2012 Jul 3. [Epub ahead of print]</citation>
    <PMID>22772426</PMID>
  </reference>
  <reference>
    <citation>Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer. 2012 Mar 15;118(6):1533-42. doi: 10.1002/cncr.26437.</citation>
    <PMID>21960118</PMID>
  </reference>
  <reference>
    <citation>Nangia-Makker P, Conklin J, Hogan V, Raz A. Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends Mol Med. 2002 Apr;8(4):187-92.</citation>
    <PMID>11927277</PMID>
  </reference>
  <reference>
    <citation>Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integr Cancer Ther. 2010 Jun;9(2):197-203. doi: 10.1177/1534735410369672. Epub 2010 May 11.</citation>
    <PMID>20462856</PMID>
  </reference>
  <reference>
    <citation>Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011 Apr 8;6(4):e18683. doi: 10.1371/journal.pone.0018683.</citation>
    <PMID>21494626</PMID>
  </reference>
  <reference>
    <citation>Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011 Aug 4;11:59. doi: 10.1186/1472-6882-11-59.</citation>
    <PMID>21816083</PMID>
  </reference>
  <reference>
    <citation>Jiang J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integr Cancer Ther. 2013 Mar;12(2):145-52. doi: 10.1177/1534735412442369. Epub 2012 Apr 24.</citation>
    <PMID>22532035</PMID>
  </reference>
  <reference>
    <citation>Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008 Dec 28;14(48):7386-91.</citation>
    <PMID>19109874</PMID>
  </reference>
  <reference>
    <citation>Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009 Sep 28;344(14):1788-91. Epub 2008 Sep 26. Review.</citation>
    <PMID>19061992</PMID>
  </reference>
  <reference>
    <citation>Zhao ZY, Liang L, Fan X, Yu Z, Hotchkiss AT, Wilk BJ, Eliaz I. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 Jul-Aug;14(4):34-8. Erratum in: Altern Ther Health Med. 2008 Nov-Dec;14(6):18.</citation>
    <PMID>18616067</PMID>
  </reference>
  <reference>
    <citation>Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification--five case reports. Forsch Komplementmed. 2007 Dec;14(6):358-64. Epub 2007 Dec 12.</citation>
    <PMID>18219211</PMID>
  </reference>
  <reference>
    <citation>Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 2007 Aug;9(8):662-70.</citation>
    <PMID>17786185</PMID>
  </reference>
  <reference>
    <citation>Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006 Oct;20(10):859-64.</citation>
    <PMID>16835878</PMID>
  </reference>
  <reference>
    <citation>Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.</citation>
    <PMID>14663471</PMID>
  </reference>
  <reference>
    <citation>Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, Raz A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002 Dec 18;94(24):1854-62.</citation>
    <PMID>12488479</PMID>
  </reference>
  <reference>
    <citation>Tehranian N, Sepehri H, Mehdipour P, Biramijamal F, Hossein-Nezhad A, Sarrafnejad A, Hajizadeh E. Combination effect of PectaSol and Doxorubicin on viability, cell cycle arrest and apoptosis in DU-145 and LNCaP prostate cancer cell lines. Cell Biol Int. 2012 Jul;36(7):601-10. doi: 10.1042/CBI20110309.</citation>
    <PMID>22214228</PMID>
  </reference>
  <reference>
    <citation>Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev. 2000 Dec;5(6):546-52.</citation>
    <PMID>11134977</PMID>
  </reference>
  <reference>
    <citation>Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995 Mar 1;87(5):348-53.</citation>
    <PMID>7853416</PMID>
  </reference>
  <reference>
    <citation>Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst. 1992 Mar 18;84(6):438-42.</citation>
    <PMID>1538421</PMID>
  </reference>
  <reference>
    <citation>Gunning AP, Bongaerts RJ, Morris VJ. Recognition of galactan components of pectin by galectin-3. FASEB J. 2009 Feb;23(2):415-24. Epub 2008 Oct 2.</citation>
    <PMID>18832596</PMID>
  </reference>
  <reference>
    <citation>Laurent C, Maria M, Pascal R, Victoria C, Ernesto MM, de Boer RA, Fran√ßoise P, Patrick L, Faiez Z, Patrick R, Natalia LA. Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arterioscler Thromb Vasc Biol. 2012 Nov 1. [Epub ahead of print]</citation>
    <PMID>23117656</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Prostate Specific Antigen</keyword>
  <keyword>Modified Citrus Pectin</keyword>
  <keyword>PectaSol-C</keyword>
  <keyword>Biochemical Relapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
